Monimus Capital Management LP Takes $845,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Monimus Capital Management LP purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,006 shares of the biotechnology company's stock, valued at approximately $845,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of VKTX. Stone House Investment Management LLC grew its holdings in shares of Viking Therapeutics by 66.7% in the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. S.A. Mason LLC grew its holdings in shares of Viking Therapeutics by 20.0% in the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock valued at $72,000 after acquiring an additional 300 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Viking Therapeutics by 75.9% in the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 309 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Viking Therapeutics by 7.4% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 345 shares in the last quarter. Finally, Arizona State Retirement System grew its holdings in Viking Therapeutics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock worth $1,164,000 after purchasing an additional 353 shares during the period. Institutional investors and hedge funds own 76.03% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Viking Therapeutics news, COO Marianna Mancini sold 54,215 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the sale, the chief operating officer now owns 374,134 shares of the company's stock, valued at approximately $15,994,228.50. This represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Greg Zante sold 50,309 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,150,709.75. Following the sale, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. This trade represents a 23.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 299,014 shares of company stock valued at $12,782,849 over the last 90 days. 4.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

VKTX has been the subject of a number of research analyst reports. Citigroup initiated coverage on Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price target for the company. Maxim Group reduced their price target on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a report on Friday, February 7th. B. Riley reiterated a "buy" rating and set a $96.00 price target (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Piper Sandler reduced their price target on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a report on Thursday, February 6th. Finally, Raymond James lifted their price target on Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Viking Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $97.67.

Viking Therapeutics Price Performance

VKTX traded down $0.37 during trading on Tuesday, hitting $29.46. 3,348,979 shares of the stock traded hands, compared to its average volume of 3,981,740. Viking Therapeutics, Inc. has a twelve month low of $24.41 and a twelve month high of $89.10. The company has a market cap of $3.31 billion, a price-to-earnings ratio of -29.46 and a beta of 0.90. The business has a 50 day moving average price of $31.94 and a 200 day moving average price of $48.41.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the business posted ($0.25) EPS. On average, equities research analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.